The following trials are ongoing in the division of Rheumatology and Immunology:
Principal Investigator- Stacy Ardoin, MD
“A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients with Active Lupus Arthritis”.
“Assessment of Transition Readiness”-Study to Assess how Teenagers and Young Adults Make the Change from Pediatric Doctors and Health Care Providers to Adult Doctors and Health Care Providers.
Investigator Initiated Trial being conducted at Nationwide Children’s Hospital
“Measure of Lupus Nephritis Activity & Damage for Children”-A Multi-Site Study to Assess the Construct and Discriminant Validity of Current Measures of Lupus Nephritis Activity in Childhood Lupus.
Sponsor: Cincinnati Children’s Hospital Medical Center/NIH, National Institute of Arthritis and Musculoskeletal and Skin Diseases. Study being conducted at Nationwide Children’s Hospital.
If you would like to participate in one of Dr. Ardoin’s clinical trials please call (614) 366-4982
Principal Investigator- Kevin Hackshaw, MD
A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects with Osteoarthritis (OA) of the Knee.
Sponsor: Stryker Biotech, LLC
A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and in combination with methotrexate (MTX), versus methotrexate in patients with early, moderate to severe rheumatoid arthritis.
Sponsor: F Hoffmann-La Roche AG
Sponsor: Human Genome Sciences, INC.
If you would like to participate in one of Dr. Hackshaw's clinical trials please contact: Francesca Madiai (614) 688-6296
Principal Investigator- Wael Jarjour, MD
“A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease (Embody 1)”
If you would like to participate in one of Dr. Jarjour’s clinical trials please call (614) 366-4982